Episode 325
What is the ASAP and what you should know about it
Interview with Greg Ball
The Effective Statistician - in association with PSI
December 11, 202348m 56s
Audio is streamed directly from the publisher (audio.podigee-cdn.net) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Interview with Greg Ball
- The US FDA has been advocating for aggregate program-level safety evaluations since 1988 when the ISS was introduced (the IND Safety Reporting Final Rule).
- Aggregate data analysis looks at all available data holistically rather than relying on individual case reports. This allows for a more complete understanding of potential risks associated with a drug or vaccine.
- In the near future, more companies will adopt a systematic approach to aggregate safety assessment planning and IND safety reporting.
- This process will develop a better understanding of the safety profile of drugs and ensure that patients’ safety is well-thought-of.
Sources and references:
Greg served in the Navy and taught HS math and physics before earning his MS in statistics from Purdue and PhD in biostatistics from the University of Texas. His research on blinded safety monitoring procedures is being developed in collaboration with statistical and clinical scientists at several pharmaceutical companies (including AbbVie and Merck). He co-leads, with Mary Nilsson, the PhUSE Safety Analytics working group. Greg established, with Bill Wang, the ASA Biopharm Safety Monitoring working group and has been pioneering the joint DIA-ASA Interdisciplinary Safety Evaluation (DAISE) scientific working group, to advocate for aggregate safety assessments and cross-disciplinary scientific engagement.
- Ball G, Kurek R, Hendrickson BA, et al (2020). Global Regulatory Landscape for Aggregate Safety Assessments: Recent Developments and Future Directions. Therapeutic Innovation & Regulatory Science, 54(2):447-461
- Ball G, Hendrickson BA, Freedman AL, Gordon R, Crowe B, Veenhuizen MF Buchanan J (2021). Interdisciplinary Safety Evaluation for Learning and Decision-Making. Therapeutic Innovation & Regulatory Science, 55:705-716.
- Hendrickson BA, Wang WW, Ball G, et al (2021). Aggregate Safety Assessment Planning for the Drug Development Life Cycle. Therapeutic Innovation & Regulatory Science, 55:717-732.
Greg Ball
Owner and Consultant at ASAP Process Consulting
Greg served in the Navy and taught HS math and physics before earning his MS in statistics from Purdue and PhD in biostatistics from the University of Texas. His research on blinded safety monitoring procedures is being developed in collaboration with statistical and clinical scientists at several pharmaceutical companies (including AbbVie and Merck). He co-leads, with Mary Nilsson, the PhUSE Safety Analytics working group. Greg established, with Bill Wang, the ASA Biopharm Safety Monitoring working group and has been pioneering the joint DIA-ASA Interdisciplinary Safety Evaluation (DAISE) scientific working group, to advocate for aggregate safety assessments and cross-disciplinary scientific engagement.